Open Angle Glaucoma Market Overview, Market Drivers, Market Barriers, Emerging Therapy and Market Report Scope


by DelveInsight Open Angle Glaucoma Market The Insights report provides an in-depth understanding of current treatment practices, emerging drugs, Open Angle Glaucoma market share of individual therapies, current and forecast Open Angle Glaucoma market size from 2019 to 2032 segmented into 7MM (US, EU5 (UK, Italy, Spain, France and Germany) and Japan).

Overview of Open-Angle Glaucoma

Glaucoma describes a group of conditions in which there is a characteristic hollowing of the optic disc with corresponding visual field defects, due to the loss of retinal ganglion cells. It is a progressive disease and the most common cause of irreversible blindness worldwide.

Download sample report @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-market

Some of the Key Features of the Open Angle Glaucoma Market Report

  • According to DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed among females, compared to males, in all 7MM countries.
  • According to analysis by DelveInsight, in 2019 there were 2,749,378 cases of open-angle glaucoma in the United States.
  • DelveInsight’s analysis shows that in 2019 there were 7,941,564 and 882,396 cases of POAG and secondary GAO respectively in 7MM.
  • Open-angle glaucoma companies such as Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp, Novartis/Alcon Research, Allergan and many others.
  • Open angle glaucoma treatments such as ROCKLATAN, Rhopressa, XELPROS (latanoprost ophthalmic emulsion) 0.005%, EYBELIS ophthalmic solution 0.002% (DE-117, Omidenepag isopropyl), VYZULTA, TAPCOM/DE-111 (tafluprost/timolol maleate) , GLANATEC, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, ZIOPTAN (tafluprost), DuoTrav PQ (travoprost/timolol), TRAVATAN Z (travoprost ophthalmic solution) 0.004%, LUMIGAN 0.01 % (bimatoprost ophthalmic solution), Bimatoprost SR -Release), and several others.

Categories of open-angle glaucoma

The two main categories of glaucoma are

  • open angle glaucoma,
  • And angle-closure glaucoma.

Types of open-angle glaucoma

Primary open-angle glaucoma (POAG) and secondary open-angle glaucoma. POAG is a subset of glaucoma defined by an open, normal-appearing anterior chamber angle and elevated intraocular pressure (IOP), with no other underlying disease. In secondary open-angle glaucoma, there is an identifiable cause of increased eye pressure, leading to optic nerve damage and loss of vision.

open angle glaucoma symptoms

The sign and symptoms of GAO include increased IOP, anterior chamber angle opening, and optic disc changes seen on clinical examination, such as an elevated cup to disc ratio , asymmetry of the cup/disc ratio between the eyes, vertical elongation of the cup, etc.

Open Angle Glaucoma Risk Factors

Risk factors for GAO include advanced age, family history of glaucoma, African ancestry, myopia, elevated IOP, low blood pressure, topical corticosteroid use, inflammation, and tumor. There are several risk factors such as age > 60, genetic predisposition, certain ocular characteristics (such as pupillary defect, thin cornea, myopia), low level of education, smoking, African ancestry and visual problems, which are associated with this indication and so the treatment model varies accordingly.

Classification of open-angle glaucoma

POAG is classified according to the age of onset, as primary congenital glaucoma (onset up to 3 years old), juvenile open-angle glaucoma (JOAG; onset between 5 and 35 years old), and POAG at age adult (after the age of 35).

Epidemiological segmentation of open-angle glaucoma in 7MM

  • Prevalent total population
  • Diagnosed prevalence by sex
  • Diagnosed prevalence by age
  • Total Prevalent Diagnosed Population
  • Prevalent population diagnosed by type

Open angle glaucoma treatment

The primary goal of glaucoma treatment is to increase quality of life through IOP reduction to preserve visual function. In the process of lowering IOP, an ideal drug should have a simple schedule to follow, disrupt the patient’s life as little as possible, be highly tolerable and affordable. However, medical treatment for glaucoma has associated side effects, complications, and costs.

Open Angle Glaucoma Market Overview

There are three mainstays for lowering eye pressure i.e. medication, laser and surgery. The two types of laser treatments currently used are Selective Laser Trabeculoplasty (SLT) and Argon Laser Trabeculoplasty (ALT). Surgery for GAO includes cataract surgery, microinvasive glaucoma surgery (MIGS), trabeculectomy, drainage implant surgery, and ciliary body removal. There is a range of drugs for lowering intraocular pressure in the OAG, which are divided into five major classes, namely prostaglandin analogues, beta-blockers, diuretics, cholinergic agonists (parasympthomimetics) and alpha agonists.

Get a preview of the report @ https://www.delveinsight.com/sample-request/open-angle-glaucoma-markeyou

Evaluating emerging treatment for open-angle glaucoma

Open angle glaucoma Treatment aims to lower IOP and thereby reduce the risk of progressive vision loss, using medication, laser therapy or conventional surgery. Open angle glaucoma Treatment options are expanding rapidly. However, there is no cure available yet.

Open Angle Glaucoma Market Drivers

  • Rich Emerging Pipeline
  • Development of advanced drugs against glaucoma
  • Patient-Friendly Dosage Regimens
  • Awareness
  • Development of treatment methods to deal with the situation of non-adherence

Open Angle Glaucoma Market Barriers

  • Lack of animal models
  • Socio-economic barriers
  • Lack of patient pool due to underdiagnosis

Contents

1. Key information

2. Executive Summary of Open Angle Glaucoma

3. Competitive Intelligence Analysis for Open Angle Glaucoma

4. Open Angle Glaucoma: Market Snapshot

5. Open-angle glaucoma: background and overview of the disease

6. Patient journey

7. Epidemiology of open-angle glaucoma and patient population

8. Treatment Algorithm, Current Treatment and Medical Practices

9. Open-angle glaucoma unmet needs

10. Key Parameters of Open-Angle Glaucoma Treatment

11. Products marketed for open-angle glaucoma

12. Emerging therapies for open-angle glaucoma

13. Open-Angle Glaucoma: Seven Key Market Insights

14. Attribute Analysis

15. 7MM: Market Outlook

16. Open Angle Glaucoma Access and Reimbursement Overview

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Abilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a business consulting and market research firm, providing expert business solutions for the life sciences verticals and offering premier consulting services in the areas of R&D, strategy formulation, operations , competitive intelligence, competitive landscape design and mergers and acquisitions.

Contact us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact: Yash Bhardwaj
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
City: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Previous Super Bowl 2022: Why Bengals and Rams kickers could add serious drama to the big game
Next Review: Damon Kowarsky's 'Traveling Without Moving' Is Tied With Mysterious Mystery | Canberra time